MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-KR-03-0077631
Naari Pharma Private Limited - pharma in Bangalore, Karnataka, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹136.35 Cr
▲ 14% YoY
Net profit · FY 2025
₹33.69 Cr
Net margin 24.7%
EBITDA · FY 2025
₹40.19 Cr
EBITDA margin 29.5%
Authorised capital
₹86.83 Cr
Registered with MCA
Paid-up capital
₹2.7 Cr
Issued & subscribed
Open charges
₹104.5 Cr
Satisfied ₹185.45 Cr
Company age
48 yrs
Est. 1978
Employees · EPFO
186
Provident fund records
About Naari Pharma Private Limited
Data last updated:
Naari Pharma Private Limited is a private limited company based in Bangalore, Karnataka, India, a subsidiary of Tenshi Pharmaceuticals Private Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 February 1978 and has been in existence for over 48 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U74899KA1978PTC142872. Its GSTIN is 29AAACI2995R1ZN (Karnataka). The company holds 9 GST registrations, of which 4 are active.
The company has an authorised share capital of ₹86.83 Cr and a paid-up capital of ₹2.7 Cr. It was formerly known as Indo Phyto Chemicals Private Limited. It is led by directors including Prithipal Singh Kochhar (Whole-Time Director) and Hermann Osterwald.
Its last annual general meeting (AGM) was held on 12 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No.30 Galaxy 1st Main Road Jp Nagar Third Phase, Bangalore, Karnataka, India – 560078.
As per the financials filed for FY 2025, the company reported a revenue of ₹136.35 Cr, a growth of 14% compared to the previous year. For the same year it recorded a net profit of ₹33.69 Cr (net margin 24.7%) and EBITDA of ₹40.19 Cr (EBITDA margin 29.5%). Revenue has grown at a compounded annual rate (CAGR) of 14% over three years and 18% over five years.
The company has about 186 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Naari. As per MCA filings, the company has open charges of ₹104.5 Cr and satisfied charges of ₹185.45 Cr on record. Court records list 6 cases involving the company, including 2 filed by the company and 4 filed against it; 2 cases are pending. The company has 17 deals on record (12 secondary share transfers, 5 funding rounds), with disclosed funding of ₹262.18 Cr; the latest was in March 2025. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Jay Formulations Ltd with revenue of ₹138.71 Cr. The company has 31 MSME Form 1 returns on record between 2017 and 2024, listing 942 overdue payments to 97 micro and small suppliers.
Naari Pharma Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-KR-03-0077631). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website naari.co.
Company Details of Naari Pharma Private Limited
CIN U74899KA1978PTC142872
Registration Number 142872
Incorporation Date 23 February 1978
ROC Bangalore
Listing Status Unlisted
Company Status Active
Date of Last AGM 12 August 2025
Date of Balance Sheet 31 March 2025
Parent Company Tenshi Pharmaceuticals Private Limited
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-KR-03-0077631
CIN History of Naari Pharma Private Limited
Naari Pharma has one previous CIN (Corporate Identification Number): U74899DL1978PTC008881. The current CIN is U74899KA1978PTC142872, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U74899KA1978PTC142872 | Current |
| U74899DL1978PTC008881 | Previous |
Key People
Prithipal Singh Kochhar Whole-Time Director Hermann Osterwald Nominee Director Pudhucode Radhakrishnan Kannan Nominee Director Recognitions & Rankings of Naari Pharma
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressPlot No.30 Galaxy 1st Main Road Jp Nagar Third Phase, Bangalore, Karnataka, India – 560078
- IndustryPharma, Drug Formulation & Development, API Manufacturers
Comprehensive company report
Naari Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business Activity of Naari Pharma Private Limited
The main business activity of Naari Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Naari Pharma Private Limited FY 2025 filings available
Naari Pharma Private Limited reported revenue of ₹136.35 Cr (up 14% YoY) for FY 2025.
Revenue · FY 2025
₹136.35 Cr ▲ 14%
Net profit · FY 2025
₹33.69 Cr margin 24.7%
EBITDA · FY 2025
₹40.19 Cr margin 29.5%
Compounded Annual Growth Rate (CAGR) of Naari Pharma Private Limited
Revenue CAGR growth
1 year
▲ 14%
3 years · compounded
▲ 14%
5 years · compounded
▲ 18%
EBITDA CAGR growth
1 year
▲ 5%
3 years · compounded
▲ 17%
5 years · compounded
▲ 42%
Revenue has grown at a compounded annual rate (CAGR) of 18% over five years, including 14% growth in the latest year. EBITDA rose 5% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Naari Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹40.19 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹33.69 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Naari Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 29.5% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 24.7% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Naari Pharma are in the company report.
Premium access
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Naari Pharma Private Limited
Naari Pharma has 4 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hermann Osterwald | Nominee Director | 30 Sep 2020 | 6 Years 0 Months | Current |
| Prithipal Singh Kochhar Also directs: Aresko Global LLP, Jagson Pal Pharmaceuticals Limited., I.K. Enterprises Private Limited and 5 more | Whole-Time Director | 15 Apr 2015 | 11 Years 6 Months | Current |
| Pudhucode Radhakrishnan Kannan Also directs: Dvise Medtech Private Limited, Serovia Pharma Private Limited, Dvise Pharma Tech Private Limited and 4 more | Nominee Director | 24 Jul 2025 | 1 Years 2 Months | Current |
| Deepak Komaregowda | Nominee Director | 06 Dec 2019 | 6 Years 10 Months | Current |
Peer Comparison of Naari Pharma Private Limited
Naari Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Jay Formulations Ltd | ₹138.71 Cr (FY 2021) | •••• | •••• | 11.0% | •••• | Ahmedabad, Gujarat, India |
| M.M. Remedies Private Limited | ₹137.33 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Llucknow, Uttar Pradesh, India |
| Palsons Derma Private Limited | ₹137.11 Cr (FY 2025) | •••• | •••• | 15.0% | •••• | Kolkata, West Bengal, India |
| Maxwell Life Science Limited | ₹136.55 Cr (FY 2025) | •••• | •••• | 67.0% | •••• | Mumbai, Maharashtra, India |
| Lewens Labs Private Limited | ₹136.52 Cr (FY 2025) | •••• | •••• | 12.0% | •••• | Bharuch, Gujarat, India |
| Naari Pharma Private Limited this company | ₹136.35 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | Bangalore, Karnataka, India |
| Zenith Drugs Limited | ₹135.93 Cr (FY 2025) | •••• | •••• | 2.0% | •••• | Indore, Madhya Pradesh, India |
| Alpa Laboratories Limited Listed | ₹135.8 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Indore, Madhya Pradesh, India |
| Ravoo's Laboratories Limited | ₹134.97 Cr (FY 2024) | •••• | •••• | 4.0% | •••• | Hyderabad, Telangana, India |
| Surabhi Industries (India) Private Limited | ₹133.75 Cr (FY 2024) | •••• | •••• | -37.0% | •••• | Hyderabad, Telangana, India |
| Vikram Thermo (India) Limited Listed | ₹133.72 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Ahmedabad, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Naari Pharma by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Naari Pharma Private Limited
Naari Pharma Private Limited is audited by DELOITTE HASKINS & SELLS LLP for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| DELOITTE HASKINS & SELLS LLP | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Naari Pharma Private Limited
Premium access
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Naari Pharma Private Limited
Open charges
₹104.5 Cr
Satisfied charges
₹185.45 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 May 2022 | Tata Capital Financial Services Limited | ₹2 Cr | Open |
| 27 Dec 2021 | Tata Capital Financial Services Limited | ₹4 Cr | Open |
| 30 Sep 2021 | Hdfc Bank Limited | ₹44.5 Cr | Open |
| 17 Feb 2020 | Others | ₹30 Cr | Open |
| 29 Nov 2019 | Tata Capital Financial Services Limited | ₹24 Cr | Open |
Total charge records: 14 View all charges
Deals & Funding of Naari Pharma Private Limited
Naari Pharma Private Limited has 17 deals on record (12 secondary share transfers, 5 funding rounds), with disclosed funding of ₹262.18 Cr; the latest was in March 2025.
Total deals
17
Secondary share transfers
12
Funding rounds
5
Disclosed funding
₹262.18 Cr
Deals on record (5 of 17)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2025 | Secondary share transfer | Undisclosed | Buyer: Tenshi Life Sciences Private Limited Seller: Ascent Capital Advisors India |
| May 2021 | Funding round | ₹33.35 Cr | Investors: Tenshi Life Sciences Private Limited , Jagsonpal Pharmaceuticals Limited, Ascent Capital Advisors India |
| Oct 2019 | Funding round | ₹140.5 Cr | Investors: Ascent Capital Advisors India, Jagsonpal Pharmaceuticals Limited, RPSK Strategic LLP |
| Mar 2019 | Funding round | ₹6 Cr | Investors: Tenshi Life Sciences Private Limited |
| Sep 2017 | Secondary share transfer | Undisclosed | Buyer: Tenshi Life Sciences Private Limited Seller: Sequent Scientific Limited |
Premium access
Full deal history
All 17 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Naari Pharma Private Limited
Naari Pharma Private Limited has 6 court cases on record: 2 filed by Naari Pharma, 4 filed against it. 2 cases are pending and 4 are disposed. Status as checked between 28 Sep 2026 and 04 Oct 2026.
Total cases
6
Filed by the company
2
Filed against the company
4
Pending
2
Disposed
4
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 3 | 1 | 2 |
| District courts | 3 | 3 | 0 |
Cases on record (5 of 6)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Writ petition | Filed by the company against Assessment Unit National Faceless Assessment Centre Income Tax Department & Ors | Pending |
| High Court of Uttarakhand | Court case (WPMS) | Filed by the company against State of Uttarakhand | Pending |
| District court, Udham Singh Nagar, Uttarakhand | Criminal case | Filed against the company by State Government | Disposed |
| High Court of Uttarakhand | Court case (WPMS) | Filed against the company by an individual | Disposed |
| District court, North East, Delhi | Court case (L I R) | Filed against the company by an individual | Disposed |
Premium access
Full case history
All 6 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Naari Pharma Private Limited
Naari Pharma Private Limited has 31 MSME Form 1 returns on record between 2017 and 2024, listing 942 overdue payments to 97 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 97)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Axacus Scientific World | •••• | •••• | •••• |
| Newtos Enviro Engineering | •••• | •••• | •••• |
| Pentagon Packaging | •••• | •••• | •••• |
Premium access
Full MSME payment history
Every supplier, amount and due date from all 31 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance at Naari Pharma Private Limited
Naari Pharma Private Limited has a workforce of 186 employees as of Mar 05, 2025.
Employee count
186
Active EPFO establishments
1
Employee growth
-15.45%
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Naari Pharma Private Limited
Naari Pharma Private Limited has 16 board changes on record since 2010: 4 appointments and 12 cessations. The latest: Pudhucode Radhakrishnan Kannan was appointed as Nominee Director on 24 Jul 2025.
Charges
A charge with Others of Rs. 30.00 Cr registered on 17 Feb 2020 with Charge ID 100330199 was modified on 21 Aug 2025.
AGM
Naari Pharma Private Limited last Annual general meeting of members was held on 12 Aug 2025 as per latest MCA records.
Appointed
Pudhucode Radhakrishnan Kannan was appointed as Nominee Director.
Filing
Naari Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Charges
A charge registered on 27 Dec 2022 via Charge ID 100688889 with Others was fully satisfied on 21 Mar 2024.
Charges
A charge registered on 16 Dec 2019 via Charge ID 100314802 with Others was fully satisfied on 15 Feb 2023.
Charges
A charge with Others amounted to Rs. 20.00 Cr with Charge ID 100688889 was registered on 27 Dec 2022.
Charges
A charge with Tata Capital Financial Services Limited of Rs. 2.00 Cr registered on 05 May 2022 with Charge ID 100577181 was modified on 04 Aug 2022.
Charges
A charge with Hdfc Bank Limited of Rs. 44.50 Cr registered on 30 Sep 2021 with Charge ID 100493211 was modified on 04 Aug 2022.
Charges
A charge registered on 11 Dec 2020 via Charge ID 100401185 with Others was fully satisfied on 12 Jul 2022.
Charges
A charge with Tata Capital Financial Services Limited amounted to Rs. 2.00 Cr with Charge ID 100577181 was registered on 05 May 2022.
Charges
A charge with Tata Capital Financial Services Limited of Rs. 4.00 Cr registered on 27 Dec 2021 with Charge ID 100524607 was modified on 31 Mar 2022.
39 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Naari Pharma Private Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Naari Pharma Private Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Naari Pharma Private Limited
Naari Pharma has 9 GST registrations: 4 active and 5 cancelled or inactive.
Total GSTINs
9
Active
4
Cancelled / inactive
5
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAACI2995R1ZN | Karnataka | Active | 17 Feb 2022 |
| 29AAACI2995R2ZM | Karnataka | Active | 28 May 2022 |
| 05AAACI2995R1ZX | Uttarakhand | Active | 01 Jul 2017 |
| 09AAACI2995R4ZM | Uttar Pradesh | Active | 01 Jun 2018 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Naari Pharma Private Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Naari Pharma Private Limited
Naari Pharma is an active private limited company based in Bangalore, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 February 1978 (48+ years old) and is registered under CIN U74899KA1978PTC142872.
Naari Pharma reported revenue of ₹136.35 Cr for FY 2025 (up 14% YoY).
Naari Pharma has 4 current directors:
- Prithipal Singh Kochhar - Whole-Time Director
- Hermann Osterwald - Nominee Director
- Pudhucode Radhakrishnan Kannan - Nominee Director
- Deepak Komaregowda - Nominee Director
Naari Pharma reported a net profit of ₹33.69 Cr (net margin 24.7%) and EBITDA of ₹40.19 Cr (EBITDA margin 29.5%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Naari Pharma is 14% over three years and 18% over five years. In the latest year (FY 2025) revenue rose 14%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Naari Pharma is 29AAACI2995R1ZN, registered in Karnataka. The company has 9 GST registrations in all, of which 4 are active and 5 are cancelled or inactive. Other active GSTINs include 29AAACI2995R2ZM (Karnataka), 05AAACI2995R1ZX (Uttarakhand), 09AAACI2995R4ZM (Uttar Pradesh).
The CIN (Corporate Identification Number) of Naari Pharma is U74899KA1978PTC142872. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Naari Pharma has 6 court cases on record: 2 filed by the company and 4 filed against it. 2 are pending. Most are in the high courts.
Naari Pharma was incorporated on 23 February 1978, making it 48+ years old. It is registered with the Registrar of Companies, Bangalore.
Naari Pharma has 17 deals on record (12 secondary share transfers, 5 funding rounds), with disclosed funding of ₹262.18 Cr; the latest was in March 2025.
The peers of Naari Pharma by revenue are Jay Formulations Ltd, M.M. Remedies Private Limited, Palsons Derma Private Limited, Maxwell Life Science Limited, Lewens Labs Private Limited and 5 more, all in the Pharma industry (Formulations).
Pudhucode Radhakrishnan Kannan was appointed as Nominee Director on 24 Jul 2025. Tarun Singh ceased to be Nominee Director on 26 Mar 2021. Hermann Osterwald was appointed as Nominee Director on 30 Sep 2020. Naari Pharma has 16 board changes on record in total.